SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-313116
Filing Date
2022-12-28
Accepted
2022-12-28 08:15:33
Documents
12
Period of Report
2022-12-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.05: Cost Associated with Exit or Disposal Activities

Document Format Files

Seq Description Document Type Size
1 8-K d418020d8k.htm   iXBRL 8-K 32379
  Complete submission text file 0001193125-22-313116.txt   152492

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA akba-20221222.xsd EX-101.SCH 2836
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20221222_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20221222_pre.xml EX-101.PRE 10803
6 EXTRACTED XBRL INSTANCE DOCUMENT d418020d8k_htm.xml XML 3279
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 221491660
SIC: 2834 Pharmaceutical Preparations